Association of Cannabinoid Specialists (ACS) wishes to reiterate that, to the extent that medical use of cannabis or cannabinoid medicines is available to the general public in any jurisdiction and supported by human-based scientific evidence, all patients must have access to such cannabinoid treatment when offered under the guidance of a duly-authorized medical prescriber.  

A Response to Pending Hearing in the Case of State of West Virginia vs. Schober

On September 24, 2024, the Association of Cannabinoid Specialists (www.cannaspecialists.com) hosted a paneled event surrounding the topic of policy and rescheduling, and what it means for patients and clinicians.

On September 24, 2024, the Association of Cannabinoid Specialists hosted a paneled event surrounding the topic of policy and rescheduling, and what it means for patients and clinicians. 

In this episode of Casual Conversations, the discussion revolves around the limitations of budtenders in the cannabis industry and the need for medical professionals in prescribing cannabis.

Recently President and Founder of the Association of Cannabinoid Specialists, Jordan Tishler, MD, was invited to participate in a panel at the Cannabis Regulators Association (CANNRA) 2024 External Stakeholder Meeting in Minneapolis, MN.

In this discussion hosted by Kelsey Engvik of the Association of Cannabinoid Specialists (ACS), the focus is on the evolution of cannabis policies in the U.S. and the unmet needs of patients. Special guests include Paul Armentano, Deputy Director of NORML, and Dr. Jordan Tishler, a cannabinoid specialist and president of ACS.

Recently, the Delaware House of Representatives, following ideas from Washington D.C., passed a law to do two things:  (1) remove the list of qualifying conditions from their medical cannabis laws, and (2) allow people over the age of 65 to “self-certify” that they need marijuana for medical purposes.

Dear Madam/Sir: I write to you to support the petitions before you to include anxiety, depression, and insomnia as qualifying conditions for medical cannabis treatment in Hawai’i.

Dear Members of the Joint Committee:

As one of the senior cannabis physicians in the Commonwealth of Massachusetts, President of the Association of Cannabis Specialists, Board Member of the Massachusetts Patient Advocacy Alliance, and former VA physician I wish to convey some very specific concerns regarding House Bill 4274. Despite vocal advocacy by a few veterans, this bill is not in the interests of veterans or other patients.